Combination Treatment in Ulcerative Colitis using 5-Aminosalysilic Acid (5-ASA) and Polysaccharide Peptide of Indonesian Ganoderma lucidum Mycelium Extract

Marcellus Simadibrata(1), Aditya Rachman(2), Felix Budimutiar(3), Paulus Simadibrata(4), Murdani Abdullah(5), Raja Mangatur Haloho(6), Anthony Eka Wijaya(7), Batara Bisuk(8), Shabrina Maharani(9), Dewi Mustikarani(10), Daniel Martin Simadibrata(11), Peter Sugita(12),


(1) Division of Gastroenterology , Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
(2) Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
(3) Department of Internal Medicine, Abdi Waluyo Hospital, Jakarta
(4) Department of Internal Medicine, Abdi Waluyo Hospital, Jakarta
(5) Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
(6) Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
(7) Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
(8) Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
(9) Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
(10) Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
(11) Faculty of Medicine, Universitas Indonesia, Jakarta
(12) PT. Sahabat Lingkungan Hidup, Surabaya
Corresponding Author

Abstract


Background:  Inflammatory bowel disease (IBD) is idiopathic disease characterized by chronic inflammation of the gastrointestinal tract. Polysaccharide peptide of Ganoderma lucidum mycelium extract (PPGL) is considerably a good option for adjunctive therapy of IBD. This study aims to evaluate the benefit of PPGL in patients treated with 5-ASA.

Method: A retrospective observational cohort study was conducted to examine the medical records of 124 ulcerative colitis patients. There were 80 patients in intervention group who were treated with a combination of 5-ASA and PPGL, and there were 44 patients in the control group who were treated with 5-ASA only. Clinical and laboratory endpoints were observed at the baseline and after 30, 60, and 90 days. Clinical endpoints included abdominal pain, bloody diarrhea, aphthous stomatitis, and polyarthritis; meanwhile, laboratory endpoints included hemoglobin level, ESR, CRP, fecal calprotectin, M2-pyruvate kinase (MP2K), fecal culture, C. difficile culture, and colonoscopy results. Clinical trials conducted after patient enrollment with registry number ClinicalTrials.gov NCT04029649.

Results: On day-30 there was a significant difference between intervention group 45.6%  and control group 2.3% in abdominal pain complaints (p < 0.001). Moreover, laboratory parameters of fecal calprotectin (p < 0.001), fecal MP2K (p = 0.015), and hemoglobin (p < 0.001) were considerably better in intervention group on day-30. These differences were consistently found on day 60 and 90.

Conclusion: The study implies potential correlation between PPGL administration and improvement of clinical and laboratory endpoints up to 90 days. A larger randomized, blinded, prospective study is required to confirm these effects in ulcerative colitis.

Keywords


ulcerative colitis; β-1,3/1,6-D-glucan; Ganoderma lucidum

Full Text: PDF

Article Metrics

Abstract View : 409 times
PDF Download : 261 times

DOI: 10.24871/24120232-11

Refbacks

  • There are currently no refbacks.